GGrantIndex
← Search

AVONEX IN TREATING HIGH DEVELOPMENT OF MULTIPLE SCLEROSIS

$48,578M01FY2000RRNIH

Ohio State University, Columbus OH

Investigators

Linked publications & trials

Abstract

Assesses the value of a recombinant human interferon beta product AVONEX in delaying the onset of clinically definite multiple sclerosis (CDMS) in subjects who have experienced a first and recent onset of a demyelinating event involving the optic nerve, spinal cord, or brainstem/cerebellum, and who are at risk for MS based on the presence of multiple magnetic resonance imaging (MRI) signal abnormalities in the brain.

View original record on NIH RePORTER →